Ascentage, based on research at University of Michigan, has increased its total funding to more than $240m after closing a $150m series C round.

Ascentage Pharma, a China-based cancer treatment based on research at University of Michigan, closed a $150m series C round yesterday. The round was co-led by healthcare-focused investment fund YuanMing Prudence Fund and Oriza Seed Venture Capital, a subsidiary of investment holding firm Suzhou Oriza Holdings. Teng Yue Partners, ArrowMark Partners, HDY International Investment, CTS Capital…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.